These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21224362)

  • 41. Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge.
    Schödel F; Peterson D; Milich DR; Charoenvit Y; Sadoff J; Wirtz R
    Behring Inst Mitt; 1997 Feb; (98):114-9. PubMed ID: 9382731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells.
    Chen JB; Wu PC; Hung AF; Chu CY; Tsai TF; Yu HM; Chang HY; Chang TW
    J Immunol; 2010 Feb; 184(4):1748-56. PubMed ID: 20083663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
    Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
    J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
    Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
    Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer.
    Feng X; Liu H; Chu X; Sun P; Huang W; Liu C; Yang X; Sun W; Bai H; Ma Y
    Acta Biomater; 2019 Dec; 100():316-325. PubMed ID: 31542504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo.
    Guan Q; Weiss CR; Qing G; Ma Y; Peng Z
    Immunotherapy; 2012 Dec; 4(12):1799-807. PubMed ID: 23240747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE.
    Baltabekova AZh; Shagyrova ZhS; Kamzina AS; Voykov M; Zhiyenbay Y; Ramanculov EM; Shustov AV
    Mol Biotechnol; 2015 Aug; 57(8):746-55. PubMed ID: 25837568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer.
    Cubas R; Zhang S; Li M; Chen C; Yao Q
    J Immunother; 2011 Apr; 34(3):251-63. PubMed ID: 21389873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.
    Schumacher J; Bacic T; Staritzbichler R; Daneschdar M; Klamp T; Arnold P; Jägle S; Türeci Ö; Markl J; Sahin U
    J Nanobiotechnology; 2018 Apr; 16(1):39. PubMed ID: 29653575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
    Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.
    Lu Y; Chan W; Ko BY; VanLang CC; Swartz JR
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12360-5. PubMed ID: 26392546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody production by injection of living cells expressing non self antigens as cell surface type II transmembrane fusion protein.
    Nizet Y; Gillet L; Schroeder H; Lecuivre C; Louahed J; Renauld JC; Gianello P; Vanderplasschen A
    J Immunol Methods; 2011 Mar; 367(1-2):70-7. PubMed ID: 21354163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
    Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
    Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
    Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications.
    Strods A; Ose V; Bogans J; Cielens I; Kalnins G; Radovica I; Kazaks A; Pumpens P; Renhofa R
    Sci Rep; 2015 Jun; 5():11639. PubMed ID: 26113394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of Breast Cancer-Related Epitopes Targeting the IGF-1 Receptor in Chimeric Human Parvovirus B19 Virus-Like Particles.
    Salazar-González JA; Ruiz-Cruz AA; Bustos-Jaimes I; Moreno-Fierros L
    Mol Biotechnol; 2019 Oct; 61(10):742-753. PubMed ID: 31317318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel rapid modularized hepatitis B core virus-like particle-based platform for personalized cancer vaccine preparation via fixed-point coupling.
    Ji M; Zhu J; Xie XX; Liu DQ; Wang B; Yu Z; Liu RT
    Nanomedicine; 2020 Aug; 28():102223. PubMed ID: 32422220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
    Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
    J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.